Chronic hepatitis C infection in the elderly

Kaohsiung Journal of Medical Sciences

Volumn 27, Issue 12, 2011, Pages 533-537

  Huang, Chung Feng ^a   Chuang, Wan Long ^b,c   Yu, Ming Lung ^c,d  

^a KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

Author keywords

Elderly; HCV; Treatment

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; RIBAVIRIN;

AGED; AGING; ANTIVIRAL THERAPY; COHORT ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GROUPS BY AGE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFE EXPECTANCY; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CARCINOGENESISS; LIVER FIBROSIS; MORTALITY; PATIENT COMPLIANCE; PREVALENCE; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGE FACTORS; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; PREVALENCE; RIBAVIRIN;

EID: 84855237694     PISSN: 1607551X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.kjms.2011.10.020     Document Type: Review

References (45)

1. G.M. Lauer, and B.D. Walker Hepatitis C virus infection N Engl J Med 345 2001 41 52 (Pubitemid 32634271)
2. T. Poynard, P. Bedossa, and P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 1997 825 832 (Pubitemid 27129209)
3. M.J. Tong, N.S. el-Farra, A.R. Reikes, and R.L. Co Clinical outcomes after transfusion-associated hepatitis C N Engl J Med 332 1995 1463 1466
4. P. Pradat, N. Voirin, H.L. Tillmann, M. Chevallier, and C. Trepo Progression to cirrhosis in hepatitis C patients: an age-dependent process Liver Int 27 2007 335 339 (Pubitemid 46416623)
5. S.D. Ryder, W.L. Irving, D.A. Jones, K.R. Neal, and J.C. Underwood Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study Gut 53 2004 451 455 (Pubitemid 38241346)
6. T. Poynard, M.F. Yuen, V. Ratziu, and C.L. Lai Viral hepatitis C Lancet 362 2003 2095 2100 (Pubitemid 38035201)
7. D. Thabut, S. Le Calvez, V. Thibault, J. Massard, M. Munteanu, and V. Di Martino Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 101 2006 1260 1267 (Pubitemid 43829992)
8. H. Hamada, H. Yatsuhashi, K. Yano, M. Daikoku, K. Arisawa, and O. Inoue Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C Cancer 95 2002 331 339 (Pubitemid 34787600)
9. J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, and V.K. Rustgi Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med 339 1998 1485 1492 (Pubitemid 28543496)
10. T. Poynard, P. Marcellin, S.S. Lee, C. Niederau, G.S. Minuk, and G. Ideo Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 352 1998 1426 1432 (Pubitemid 28510876)
11. Y. Iwasaki, K. Takaguchi, H. Ikeda, Y. Makino, Y. Araki, and M. Ando Risk factors for hepatocellular carcinoma in hepatitis C patients with sustained virologic response to interferon therapy Liver Int 24 2004 603 610 (Pubitemid 40028613)
12. W.L. Chuang, M.L. Yu, C.Y. Dai, and W.Y. Chang Treatment of chronic hepatitis C in southern Taiwan Intervirology 49 2006 99 106
13. J.F. Yang, C.I. Lin, J.F. Huang, C.Y. Dai, W.Y. Lin, and C.K. Ho Viral hepatitis infections in southern Taiwan: a multicenter community-based study Kaohsiung J Med Sci 26 2010 461 469
14. G.L. Armstrong, A. Wasley, E.P. Simard, G.M. McQuillan, W.L. Kuhnert, and M.J. Alter The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 2006 705 714 (Pubitemid 46780630)
15. T. Honda, Y. Katano, F. Urano, M. Murayama, K. Hayashi, and M. Ishigami Efficacy of ribavirin plus interferon-alpha in patients aged ≥60 years with chronic hepatitis C J Gastroenterol Hepatol 22 2007 989 995 (Pubitemid 47019853)
16. T. Kumada, H. Toyoda, T. Honda, T. Kuzuya, Y. Katano, and I. Nakano Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan Intervirology 49 2006 112 118 (Pubitemid 41318186)
17. Y. Iwasaki, H. Ikeda, Y. Araki, T. Osawa, K. Kita, and M. Ando Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C Hepatology 43 2006 54 63 (Pubitemid 43733592)
18. N. Hiramatsu, T. Oze, N. Tsuda, N. Kurashige, K. Koga, and T. Toyama Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? Hepatol Res 35 2006 185 189
19. A. Floreani, E. Minola, I. Carderi, F. Ferrara, E.R. Rizzotto, and V. Baldo Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C? J Am Geriatr Soc 54 2006 549 550 (Pubitemid 43327180)
20. C.G. Nudo, P. Wong, N. Hilzenrat, and M. Deschenes Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C Can J Gastroenterol 20 2006 589 592 (Pubitemid 44596401)
21. G. Antonucci, M.A. Longo, C. Angeletti, F. Vairo, A. Oliva, and U.V. Comandini The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr Am J Gastroenterol 102 2007 1383 1391 (Pubitemid 46976284)
22. R. Koyama, Y. Arase, K. Ikeda, F. Suzuki, Y. Suzuki, and S. Saitoh Efficacy of interferon therapy in elderly patients with chronic hepatitis C Intervirology 49 2006 121 126 (Pubitemid 43131543)
23. N. Alessi, M.A. Freni, A. Spadaro, A. Ajello, S. Turiano, and D. Migliorato Efficacy of interferon treatment (IFN) in elderly patients with chronic hepatitis C. Infez Med 11 2003 208 212 (Pubitemid 38160428)
24. C.F. Huang, J.F. Yang, C.Y. Dai, J.F. Huang, N.J. Hou, and M.Y. Hsieh Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C J Infect Dis 201 2010 751 759
25. M. Kainuma, N. Furusyo, E. Kajiwara, K. Takahashi, H. Nomura, and Y. Tanabe Pegylated interferon alpha-2b plus ribavirin for older patients with chronic hepatitis C World J Gastroenterol 16 2010 4400 4409
26. J.F. Huang, M.L. Yu, C.M. Lee, C.Y. Dai, N.J. Hou, and M.Y. Hsieh Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan Aliment Pharmacol Ther 25 2007 1029 1037
27. M.L. Yu, S.M. Lin, W.L. Chuang, C.Y. Dai, J.H. Wang, and S.N. Lu A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan Antivir Ther 11 2006 985 994
28. M.L. Yu, C.F. Huang, C.Y. Dai, J.F. Huang, and W.L. Chuang Long-term effects of interferon-based therapy for chronic hepatitis C Oncology 72 Suppl. 1 2007 16 23
29. Y. Imai, A. Kasahara, H. Tanaka, T. Okanoue, N. Hiramatsu, and H. Tsubouchi Interferon therapy for aged patients with chronic hepatitis C: Improved survival in patients exhibiting a biochemical response J Gastroenterol 39 2004 1069 1077 (Pubitemid 39618790)
30. Y. Arase, K. Ikeda, F. Suzuki, Y. Suzuki, S. Saitoh, and M. Kobayashi Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C Intervirology 50 2007 16 23 (Pubitemid 46005267)
31. K. Ikeda, Y. Arase, Y. Kawamura, H. Yatsuji, H. Sezaki, and T. Hosaka Necessities of interferon therapy in elderly patients with chronic hepatitis C Am J Med 122 2009 479 486
32. T. Poynard, V. Ratziu, F. Charlotte, Z. Goodman, J. McHutchison, and J. Albrecht Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C J Hepatol 34 2001 730 739 (Pubitemid 32488789)
33. K.R. Reddy, D. Messinger, M. Popescu, and S.J. Hadziyannis Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients J Viral Hepat 16 2009 724 731
34. T. Honda, Y. Katano, J. Shimizu, Y. Ishizu, M. Doizaki, and K. Hayashi Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver Int 30 2010 527 537
35. M.L. Yu, C.Y. Dai, J.F. Huang, N.J. Hou, L.P. Lee, and M.Y. Hsieh A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C Gut 56 2007 553 559
36. M.L. Yu, C.Y. Dai, J.F. Huang, C.F. Chiu, Y.H. Yang, and N.J. Hou Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial Hepatology 47 2008 1884 1893
37. M.A. Balogun, M.E. Ramsay, L.M. Hesketh, N. Andrews, K.P. Osborne, and N.J. Gay The prevalence of hepatitis C in England and Wales J Infect 45 2002 219 226 (Pubitemid 36104853)
38. C.H. Chen, P.M. Yang, G.T. Huang, H.S. Lee, J.L. Sung, and J.C. Sheu Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants J Formos Med Assoc 106 2007 148 155
39. R. Cozzolongo, A.R. Osella, S. Elba, J. Petruzzi, G. Buongiorno, and V. Giannuzzi Epidemiology of HCV infection in the general population: A survey in a southern Italian town Am J Gastroenterol 104 2009 2740 2746
40. J. Tanaka, J. Kumagai, K. Katayama, Y. Komiya, M. Mizui, and R. Yamanaka Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000 Intervirology 47 2004 32 40 (Pubitemid 38420865)
41. A. Dominguez, M. Bruguera, J. Vidal, P. Plans, and L. Salleras Community-based seroepidemiological survey of HCV infection in Catalonia Spain. J Med Virol 65 2001 688 693 (Pubitemid 33135096)
42. Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol;82:546-555.
43. E. Minola, D. Prati, F. Suter, F. Maggiolo, F. Caprioli, and A. Sonzogni Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C Blood 99 2002 4588 4591 (Pubitemid 34627231)
44. M. Ikeda, S. Fujiyama, M. Tanaka, M. Sata, T. Ide, and H. Yatsuhashi Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon J Gastroenterol 40 2005 148 156 (Pubitemid 40425202)
45. H. Tokita, H. Fukui, A. Tanaka, H. Kamitsukasa, M. Yagura, and H. Harada Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy J Gastroenterol Hepatol 20 2005 752 758 (Pubitemid 40733371)